Shareholders Will Be Pleased With The Quality of Qyuns Therapeutics' (HKG:2509) Earnings

Qyuns Therapeutics Co., Ltd. (HKG:2509) just reported healthy earnings but the stock price didn't move much. We think that investors have missed some encouraging factors underlying the profit figures.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

A Closer Look At Qyuns Therapeutics' Earnings

As finance nerds would already know, the accrual ratio from cashflow is a key measure for assessing how well a company's free cash flow (FCF) matches its profit. To get the accrual ratio we first subtract FCF from profit for a period, and then divide that number by the average operating assets for the period. The ratio shows us how much a company's profit exceeds its FCF.

That means a negative accrual ratio is a good thing, because it shows that the company is bringing in more free cash flow than its profit would suggest. While having an accrual ratio above zero is of little concern, we do think it's worth noting when a company has a relatively high accrual ratio. Notably, there is some academic evidence that suggests that a high accrual ratio is a bad sign for near-term profits, generally speaking.

Qyuns Therapeutics has an accrual ratio of -0.42 for the year to December 2025. That indicates that its free cash flow quite significantly exceeded its statutory profit. Indeed, in the last twelve months it reported free cash flow of CN¥400m, well over the CN¥314.5m it reported in profit. Given that Qyuns Therapeutics had negative free cash flow in the prior corresponding period, the trailing twelve month resul of CN¥400m would seem to be a step in the right direction.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Qyuns Therapeutics' Profit Performance

As we discussed above, Qyuns Therapeutics' accrual ratio indicates strong conversion of profit to free cash flow, which is a positive for the company. Because of this, we think Qyuns Therapeutics' underlying earnings potential is as good as, or possibly even better, than the statutory profit makes it seem! And it's also positive that the company showed enough improvement to book a profit this year, after losing money last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. So while earnings quality is important, it's equally important to consider the risks facing Qyuns Therapeutics at this point in time. In terms of investment risks, we've identified 1 warning sign with Qyuns Therapeutics, and understanding it should be part of your investment process.

This note has only looked at a single factor that sheds light on the nature of Qyuns Therapeutics' profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.